We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
Read MoreHide Full Article
Key Takeaways
ABT received CE Mark for Libre Duo systems, the first dual glucose-ketone sensing technology.
Abbott's new sensors track glucose and ketones every minute to help identify rising DKA risk.
Libre Duo links to Abbott's digital ecosystem and may connect with automated insulin systems.
Abbott (ABT - Free Report) recently announced that it has obtained CE Mark for Libre Duo and Libre Duo 10 Day, the world's first dual glucose-ketone sensing technology for people with diabetes. The two-in-one biowearables continuously measure glucose and ketone levels every minute, enabling real-time visibility into both glucose levels needed for daily diabetes management and rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency.
With Libre Duo systems, people with diabetes will be able to monitor ketones without traditional blood or urine tests for the first time. Abbott said that it plans to begin their commercial rollouts in select European countries later this year.
ABT Stock’s Likely Trend Following the News
Since the May 27 announcement, Abbott shares moved down 0.1%, finishing at $85.60 on Friday. On a positive note, the latest development reflects the company’s long-standing focus on health tech innovation. Given the risk of serious complications being a daily concern for people living with diabetes, the new Libre Duo systems are intended to provide clearer and earlier information about what is happening inside their bodies, allowing them to take action sooner when needed. We expect the news to help support a rebound in ABT stock’s performance.
Abbott holds a market capitalization of $149.10 billion. The company’s earnings yield of 6.4% favorably compares with the industry’s yield of 2.7%. ABT delivered an average earnings beat of 0.42% in the trailing four quarters.
Relevance of Abbott’s New Libre Duo Systems
In people with diabetes, DKA occurs when insufficient insulin prompts the body to break down fat for energy, causing ketones in the blood to rise to dangerous levels. According to the American Diabetes Association, elevated ketones can progress to DKA within hours and, if left untreated, may result in coma or death.Despite clinical guidance recommending ketone testing during illness or periods of high glucose levels, early detection remains a significant challenge.
Image Source: Zacks Investment Research
Abbott’s Libre Duo delivers up to 15 days of wear and will be offered to adults aged 18 and older. Meanwhile, Libre Duo 10 Day offers up to 10 days of wear and is intended for people aged two and older. Clinical data indicate that a 10-day sensor can help active youth complete the full wear period. Both sensors deliver consistent, strong accuracy.
The systems will integrate with Abbott's Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors.
According to the company, the Libre Duo systems align with recommendations outlined in a recent international expert consensus paper from Breakthrough T1D, a global organization focused on Type 1 diabetes research and advocacy, which describes the safe and effective use of continuous ketone monitoring as part of diabetes management.
Industry Prospects Favor ABT
According to Grand View Research, the global blood ketone meter market was valued at $488 million in 2024 and is projected to expand at a CAGR of 6.96% through 2025-2030. Some of the major factors driving the market’s growth include the increasing prevalence of diabetes, rising adoption of ketogenic and low-carbohydrate diets, and growing health awareness among consumers.
More Updates From Abbott
In April, Abbott secured FDA clearance and CE Mark for its next-generation Ultreon 3.0 Software. This marks a pivotal step in bringing coronary imaging and AI-automated insights together in one system to support better patient outcomes and help reduce risks.
ABT Stock Price Performance
Over the past year, Abbott shares have dropped 35.9%, well below the industry’s 30.6% fall.
Globus Medical shares have risen 38.9% over the past year. Estimates for the company’s 2026 earnings per share (EPS) have jumped 6.3% to $4.74 in the past 30 days. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.26%. In the last reported quarter, it posted an earnings surprise of 21.74%.
Estimates for Align Technology’s 2026 EPS have increased 1% to $11.36 in the past 30 days. Shares of the company have fallen 2% over the past year against the industry’s growth of 4.4%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 7.80%. In the last reported quarter, it delivered an earnings surprise of 14.16%.
Estimates for Integra LifeSciences’ 2026 EPS have increased 4.3% to $2.42 in the past 30 days. Shares of the company have rallied 30.2% over the past year compared with the industry’s 3.7% rise. IART’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.75%. In the last reported quarter, it delivered an earnings surprise of 31.71%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
Key Takeaways
Abbott (ABT - Free Report) recently announced that it has obtained CE Mark for Libre Duo and Libre Duo 10 Day, the world's first dual glucose-ketone sensing technology for people with diabetes. The two-in-one biowearables continuously measure glucose and ketone levels every minute, enabling real-time visibility into both glucose levels needed for daily diabetes management and rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency.
With Libre Duo systems, people with diabetes will be able to monitor ketones without traditional blood or urine tests for the first time. Abbott said that it plans to begin their commercial rollouts in select European countries later this year.
ABT Stock’s Likely Trend Following the News
Since the May 27 announcement, Abbott shares moved down 0.1%, finishing at $85.60 on Friday. On a positive note, the latest development reflects the company’s long-standing focus on health tech innovation. Given the risk of serious complications being a daily concern for people living with diabetes, the new Libre Duo systems are intended to provide clearer and earlier information about what is happening inside their bodies, allowing them to take action sooner when needed. We expect the news to help support a rebound in ABT stock’s performance.
Abbott holds a market capitalization of $149.10 billion. The company’s earnings yield of 6.4% favorably compares with the industry’s yield of 2.7%. ABT delivered an average earnings beat of 0.42% in the trailing four quarters.
Relevance of Abbott’s New Libre Duo Systems
In people with diabetes, DKA occurs when insufficient insulin prompts the body to break down fat for energy, causing ketones in the blood to rise to dangerous levels. According to the American Diabetes Association, elevated ketones can progress to DKA within hours and, if left untreated, may result in coma or death.Despite clinical guidance recommending ketone testing during illness or periods of high glucose levels, early detection remains a significant challenge.
Image Source: Zacks Investment Research
Abbott’s Libre Duo delivers up to 15 days of wear and will be offered to adults aged 18 and older. Meanwhile, Libre Duo 10 Day offers up to 10 days of wear and is intended for people aged two and older. Clinical data indicate that a 10-day sensor can help active youth complete the full wear period. Both sensors deliver consistent, strong accuracy.
The systems will integrate with Abbott's Libre digital health ecosystem, enabling users to share glucose and ketone data with caregivers and healthcare providers. Abbott is also working with leading pump companies to allow automated insulin delivery (AID) systems to connect with the sensors.
According to the company, the Libre Duo systems align with recommendations outlined in a recent international expert consensus paper from Breakthrough T1D, a global organization focused on Type 1 diabetes research and advocacy, which describes the safe and effective use of continuous ketone monitoring as part of diabetes management.
Industry Prospects Favor ABT
According to Grand View Research, the global blood ketone meter market was valued at $488 million in 2024 and is projected to expand at a CAGR of 6.96% through 2025-2030. Some of the major factors driving the market’s growth include the increasing prevalence of diabetes, rising adoption of ketogenic and low-carbohydrate diets, and growing health awareness among consumers.
More Updates From Abbott
In April, Abbott secured FDA clearance and CE Mark for its next-generation Ultreon 3.0 Software. This marks a pivotal step in bringing coronary imaging and AI-automated insights together in one system to support better patient outcomes and help reduce risks.
ABT Stock Price Performance
Over the past year, Abbott shares have dropped 35.9%, well below the industry’s 30.6% fall.
ABT’s Zacks Rank and Key Picks
Abbott currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) . While GMED sports a Zacks Rank #1 (Strong Buy), ALGN and IART each carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Globus Medical shares have risen 38.9% over the past year. Estimates for the company’s 2026 earnings per share (EPS) have jumped 6.3% to $4.74 in the past 30 days. GMED’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.26%. In the last reported quarter, it posted an earnings surprise of 21.74%.
Estimates for Align Technology’s 2026 EPS have increased 1% to $11.36 in the past 30 days. Shares of the company have fallen 2% over the past year against the industry’s growth of 4.4%. ALGN’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 7.80%. In the last reported quarter, it delivered an earnings surprise of 14.16%.
Estimates for Integra LifeSciences’ 2026 EPS have increased 4.3% to $2.42 in the past 30 days. Shares of the company have rallied 30.2% over the past year compared with the industry’s 3.7% rise. IART’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.75%. In the last reported quarter, it delivered an earnings surprise of 31.71%.